Olomoucine

Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM) [1][2]. Olomoucine regulates cell cycle and shows anti-melanin tumor activity[3][4].

Product Specifications

CAS Number

[101622-51-9]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Others; Cancer

Assay Protocol

https://www.medchemexpress.com/olomoucine.html

Purity

99.88

Solubility

DMSO : 66.67 mg/mL (ultrasonic)

Smiles

CN1C=NC2=C(NCC3=CC=CC=C3)N=C(NCCO)N=C12

Molecular Formula

C15H18N6O

Molecular Weight

298.34

Precautions

H315, H319, H335

References & Citations

[1]Vesely, J., Havlicek, J., Strnad, M., et al. Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-786 (1994) .|[2]Abraham, R.T., Acquarone, M., Andersen, A., et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83 (2), 105-120 (1995) .|[3]Hajdúch M, et al. Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs. 1997 Nov. 8 (10) :1007-13.|[4]Raynaud FI, et al. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther. 2004 Mar. 3 (3) :353-62.